Smith & Nephew plc (ETR:NPW1)

Germany flag Germany · Delayed Price · Currency is EUR
12.60
-0.10 (-0.79%)
Last updated: Jun 3, 2026, 8:05 AM CET
Market Cap10.79B -4.5%
Revenue (ttm)5.25B +6.1%
Net Income532.31M +51.7%
EPS0.61 +52.3%
Shares Out n/a
PE Ratio20.26
Forward PE13.27
Dividend0.33 (2.60%)
Ex-Dividend DateMar 26, 2026
Volumen/a
Open12.60
Previous Close12.70
Day's Range12.60 - 12.60
52-Week Range12.50 - 16.57
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 4, 2026

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 1856
Employees 16,988
Stock Exchange Deutsche Börse Xetra
Ticker Symbol NPW1

Financial Performance

In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.

Financial numbers in USD Financial Statements

News

Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform d...

1 day ago - GlobeNewsWire

Smith & Nephew added to European Conviction List at Goldman Sachs

Goldman Sachs analysts added Smith & Nephew to the firm’s European Conviction List as part of its monthly update. The company’s guidance reset brings an opportunity to revisit a name…

2 days ago - TheFly

Smith & Nephew Slides: Investor presentation

Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.

7 days ago - Filings

Smith & Nephew price target lowered to 1,550 GBp at Goldman Sachs

Goldman Sachs analyst Richard Felton lowered the firm’s price target on Smith & Nephew to 1,550 GBp from 1,700 GBp and keeps a Buy rating on the shares. The firm…

9 days ago - TheFly

Smith & Nephew price target lowered to $30 from $32 at Canaccord

Canaccord lowered the firm’s price target on Smith & Nephew to $30 from $32 and keeps a Hold rating on the shares. The firm updated its model following Q1 results…

22 days ago - TheFly

Smith & Nephew price target lowered to $31.85 from $36.20 at Bernstein

Bernstein lowered the firm’s price target on Smith & Nephew to $31.85 from $36.20 and keeps a Market Perform rating on the shares after the company provided a Q1 trading…

22 days ago - TheFly

Smith & Nephew price target raised to 1,350 GBp from 1,300 GBp at Barclays

Barclays raised the firm’s price target on Smith & Nephew to 1,350 GBp from 1,300 GBp and keeps an Equal Weight rating on the shares. Th firm updated the company’s…

26 days ago - TheFly

Smith & Nephew Earnings Call Transcript: Q1 2026

Q1 delivered 3.1% underlying growth, led by Sports Medicine and resilient Advanced Wound Management, offsetting softness in U.S. knees. Full-year guidance is reaffirmed, with a $500 million share buyback announced and strong cash generation supporting future growth.

4 weeks ago - Transcripts

Smith & Nephew Slides: Q1 2026

Smith & Nephew has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.

4 weeks ago - Filings

Smith & Nephew Earnings release: Q1 2026

Smith & Nephew released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.

4 weeks ago - Filings

UK's Smith+Nephew keeps annual outlook, plans share buyback as quarterly revenue rises

Medical products maker ​Smith+Nephew posted ‌a 3.1% rise ​in ​first-quarter underlying revenue on ⁠Wednesday, ​helped by ​strong sports medicine and wound ​management ​performance, and kept ‌its ⁠annu...

4 weeks ago - Reuters

Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming Europ...

4 weeks ago - GlobeNewsWire

Smith & Nephew price target lowered to $32 from $35 at Canaccord

Canaccord analyst Caitlin Cronin lowered the firm’s price target on Smith & Nephew to $32 from $35 and keeps a Hold rating on the shares. The firm updated its model…

5 weeks ago - TheFly

Smith & Nephew announces evidence for Cartiheal Agili-C Cartilage Repair

Smith+Nephew announces further evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its Cartiheal Agili-C Cartilage Repair Implant recently published in th...

6 weeks ago - TheFly

Smith & Nephew reports positive trial data for Regeneten implant

Smith & Nephew announced compelling new randomized control trial data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the Regeneten bioi...

7 weeks ago - TheFly

Smith & Nephew Slides: Investor presentation

Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.

2 months ago - Filings

Smith & Nephew price target raised to 1,507 GBp from 1,482 GBp at Morgan Stanley

Morgan Stanley raised the firm’s price target on Smith & Nephew to 1,507 GBp from 1,482 GBp and keeps an Overweight rating on the shares.

2 months ago - TheFly

Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed...

3 months ago - GlobeNewsWire

Smith & Nephew price target raised to $35 from $34 at Canaccord

Canaccord raised the firm’s price target on Smith & Nephew to $35 from $34 and keeps a Hold rating on the shares. The firm said they delivered a solid quarter,…

3 months ago - TheFly

Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026

Smith+Nephew announces it will feature handheld robotics during the American Academy of Orthopedic Surgeons (AAOS) Annual meeting in New Orleans this week.

3 months ago - GlobeNewsWire

Smith & Nephew price target raised to 1,305 GBp from 1,290 GBp at Barclays

Barclays raised the firm’s price target on Smith & Nephew to 1,305 GBp from 1,290 GBp and keeps an Equal Weight rating on the shares.

3 months ago - TheFly

Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026

Uniting the most advanced technologies for biomechanical repair and biological augmentation  Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase it...

3 months ago - GlobeNewsWire

Smith & Nephew Earnings Call Transcript: Q4 2025

Delivered strong FY2025 results with 5.3% revenue growth, 160 bps margin expansion, and $840M free cash flow. 2026 guidance targets 6% organic revenue growth and $1.3B trading profit, with innovation and new launches driving performance.

3 months ago - Transcripts

Smith & Nephew Annual report: Q4 2025

Smith & Nephew has published its Q4 2025 annual report on March 2, 2026.

3 months ago - Filings

Smith & Nephew Annual report: Q4 2025

Smith & Nephew has published its Q4 2025 annual report on March 2, 2026.

3 months ago - Filings